Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ERSP on Zone

This article was originally published in The Tan Sheet

Executive Summary

Zone Labs has discontinued and modified several performance claims and a comparative claim in online ads for its Zone OmegaRx Capsules in light of a review by the Electronic Retailing Self-Regulation Program, the Council of Better Business Bureaus unit announces Nov. 29. In a case brought by an anonymous challenger, ERSP evaluated a number of claims including that Zone Labs' product is "the quickest and easiest way to control inflammation within the fat cells." However, during the case Zone Labs revised online ads and discontinued performance claims at issue. ERSP determined the claims at issue were "modified in a manner that was consistent with the marketer's substantiating data"...

Zone Labs has discontinued and modified several performance claims and a comparative claim in online ads for its Zone OmegaRx Capsules in light of a review by the Electronic Retailing Self-Regulation Program, the Council of Better Business Bureaus unit announces Nov. 29. In a case brought by an anonymous challenger, ERSP evaluated a number of claims including that Zone Labs' product is "the quickest and easiest way to control inflammation within the fat cells." However, during the case Zone Labs revised online ads and discontinued performance claims at issue. ERSP determined the claims at issue were "modified in a manner that was consistent with the marketer's substantiating data"....

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS101150

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel